IRIMAD Interest of postoperative reintroduction of chemotherapy in patients with colorectal liver metastases who responded well to preoperative chemotherapy with FOLFIRI with or without targeted therapy

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-504831-42-00

Acronym

APHP220917

Enrollment

254

Registered

2024-05-23

Start date

2025-06-27

Completion date

Unknown

Last updated

2025-07-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patient with colorectal cancer with hepatic metastasis

Brief summary

Disease-free survival rate at 3 years

Detailed description

Overall survival at 3 years, Liver-free survival at 3 years, Extra -hepatic recurrence rate, Safety including chemotherapy associated toxicity assessed by International Common Terminology Criteria for Adverse Events (CTCAE) grading system, Compliance defined as the ability to administrate a total of 12 cycles of FOLFIRI-based chemotherapy including preoperative treatment, Rate of treatment of recurrence with curative intent

Interventions

DRUGONDANSETRON

DRUGIRINOTECAN

DRUGCALCIUM FOLINATE

DRUGCALCIUM LEVOFOLINATE

DRUGFLUOROURACIL

DRUGMETHYLPREDNISOLONE

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Disease-free survival rate at 3 years	—

Secondary

Measure	Time frame
Overall survival at 3 years, Liver-free survival at 3 years, Extra -hepatic recurrence rate, Safety including chemotherapy associated toxicity assessed by International Common Terminology Criteria for Adverse Events (CTCAE) grading system, Compliance defined as the ability to administrate a total of 12 cycles of FOLFIRI-based chemotherapy including preoperative treatment, Rate of treatment of recurrence with curative intent	—

Measure

Time frame

—

Countries

France

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026